Caladrius Biosciences to Participate at Upcoming November Conferences
October 31 2019 - 8:30AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a late-stage therapeutics development biopharmaceutical
company pioneering advancements of cell therapies in select
cardiovascular and autoimmune diseases, announced today that the
Company will participate in the following conferences in November:
LSX Inv€$tival Showcase in Partnership with
Jefferies
Date
& Time: |
Tuesday, November 19, 2019 at 11:15 (GMT) |
Presenter: |
David J. Mazzo, Ph.D., President
and Chief Executive Officer of Caladrius Biosciences |
Location: |
Hilton Waldorf in London, UK |
Management will host one-on-one meetings at the showcase and the
Jefferies 2019 London Healthcare Conference. To inquire about
arranging a meeting with management, please contact John Menditto,
Vice President of Investor Relations and Corporate
Communications.
American Heart Association Scientific Sessions
2019
Abstract Title: |
Clinical Trial of Autologous CD34
Cell Therapy for Treatment of Coronary Microvascular Dysfunction in
Patients with Angina and Non-obstructive Coronary Arteries |
Date & Time: |
Saturday, November 16, 2019 at
3:35pm (ET) |
Presenter: |
C. Noel Bairey Merz, M.D.,
Director of Barbra Streisand Women's Heart Center at
Cedars-Sinai |
Location: |
Philadelphia, Pennsylvania |
Dr. Noel Bairey Merz is on Caladrius’ cardiovascular disease
scientific advisory board and will be presenting the preliminary
results from our Phase 2 ESCaPE-CMD study in patients with coronary
microvascular dysfunction.
About Caladrius BiosciencesCaladrius is a
late-stage therapeutics development biopharmaceutical company
pioneering advancements of cell therapies for select cardiovascular
and autoimmune diseases. Our leadership team collectively has
decades of biopharmaceutical development experience and
world-recognized scientific achievement in the fields of
cardiovascular and autoimmune disease, among other areas. Our
current product candidates include three developmental treatments
for cardiovascular diseases based on our CD34+ cell therapy
platform: CLBS12, recipient of a SAKIGAKE designation in Japan and
advanced therapy medicinal product classification (ATMP) in Europe,
eligible for early conditional approval for the treatment of
critical limb ischemia in Japan based on an ongoing clinical trial;
CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial
in the U.S.A. for the treatment of coronary microvascular
dysfunction; and CLBS14, recipient of a RMAT designation in the
U.S.A. and for which we are in preparation to commence a Phase 3
clinical trial in no option refractory disabling angina. For more
information on the company, please
visit www.caladrius.com.
Contact:
Investors: Caladrius Biosciences, Inc. John Menditto Vice
President, Investor Relations and Corporate Communications Phone:
+1-908-842-0084 Email: jmenditto@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2023 to Apr 2024